Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145676 · ClinicalTrials.gov registry record · Phase 3
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT02145676: Clinical Trial Phase 3 study, sponsored by Allergan.
NCT02145676 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 53 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02145676, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
Primary Outcome
The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the elbow flexors by passively moving the elbow flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.
Interventions
- BIOLOGICAL onabotulinumtoxinA
- DRUG placebo (normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Why NCT02145676 stopped before completion
NCT02145676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which onabotulinumtoxinA is the first listed.
NCT02145676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02145676 about?
NCT02145676 is a clinical study titled "OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity". This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
What is the current status of trial NCT02145676?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2014-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02145676?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL), placebo (normal saline) (DRUG).
Who is sponsoring clinical trial NCT02145676?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02145676's enrollment target sits among peer trials
53 1839th of 2000 higher than 160 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia